Robert F. Williamson III Purchases 22,192 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III bought 22,192 shares of the stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the acquisition, the director now directly owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. This represents a 45.62 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $1.96 on Wednesday. Perspective Therapeutics, Inc. has a 1-year low of $1.90 and a 1-year high of $19.05. The company’s 50-day moving average is $2.88 and its 200 day moving average is $6.10.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics in the 4th quarter valued at $33,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at $34,000. National Bank of Canada FI boosted its stake in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares during the period. ProShare Advisors LLC grew its holdings in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in Perspective Therapeutics in the 4th quarter worth about $51,000. 54.66% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CATX has been the topic of several recent research reports. Royal Bank of Canada decreased their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. Scotiabank started coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.